Page last updated: 2024-11-05

thalidomide and Fever

thalidomide has been researched along with Fever in 15 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.

Research Excerpts

ExcerptRelevanceReference
"Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma."7.74Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007)
" A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)."6.79A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014)
"Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month."5.91Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023)
" We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis."5.17Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013)
"Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma."3.74Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007)
" A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)."2.79A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014)
"Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL)."2.78Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. ( Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG, 2013)
"Environmental causes of birth defects have increasingly been recognized since the mid-20th century."2.47Causes of birth defects: lessons from history. ( Lancaster, PA, 2011)
"Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month."1.91Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.67)18.7374
1990's2 (13.33)18.2507
2000's4 (26.67)29.6817
2010's5 (33.33)24.3611
2020's3 (20.00)2.80

Authors

AuthorsStudies
Banday, AZ1
Joshi, V1
Arora, K1
Sadanand, R1
Basu, S1
Pilania, RK1
Jindal, AK1
Vignesh, P1
Gupta, A1
Sharma, S1
Dhaliwal, M1
Rawat, A1
Singh, S1
Suri, D1
Li, Y1
Deng, M1
Han, T1
Mo, W1
Mao, H1
Soriano, A1
Soriano, M1
Espinosa, G1
Manna, R1
Emmi, G1
Cantarini, L1
Hernández-Rodríguez, J1
Gruson, B1
Lortholary, O1
Canioni, D1
Chandesris, O1
Lanternier, F1
Bruneau, J1
Grosbois, B1
Livideanu, C1
Larroche, C1
Durieu, I1
Barete, S1
Sevestre, H1
Diouf, M1
Chaby, G1
Marolleau, JP1
Dubreuil, P1
Hermine, O1
Damaj, G1
Geng, C1
Hou, J1
Zhao, Y1
Ke, X1
Wang, Z1
Qiu, L1
Xi, H1
Wang, F1
Wei, N1
Liu, Y1
Yang, S1
Wei, P1
Zheng, X1
Huang, Z1
Zhu, B1
Chen, WM1
Lai, YT1
Tsai, YP1
Cherng, CG1
Ke, JJ1
Ho, MC1
Tsai, CW1
Yu, L1
Lancaster, PA1
Morita, Y1
Shimada, T1
Yamaguchi, T1
Rai, S1
Hirase, C1
Emoto, M1
Serizawa, K1
Taniguchi, Y1
Ojima, M1
Tatsumi, Y1
Ashida, T1
Matsumura, I1
Badoux, XC1
Keating, MJ1
Wen, S1
Wierda, WG1
O'Brien, SM1
Faderl, S1
Sargent, R1
Burger, JA1
Ferrajoli, A1
Marque, M1
Guillot, B1
Bessis, D1
Thornburg, A1
Abonour, R1
Smith, P1
Knox, K1
Twigg, HL1
Haslett, P1
Tramontana, J1
Burroughs, M1
Hempstead, M1
Kaplan, G1
Deaner, P1
Drenth, JP1
Vonk, AG1
Simon, A1
Powell, R1
van der Meer, JW1
DeFeo, C1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292[NCT00759603]Phase 260 participants (Actual)Interventional2008-09-30Completed
[NCT00004276]Phase 250 participants Interventional1990-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group Guidelines

Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly & constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes>1500/µL, platelets>100,000/µL, hemoglobin>11.0 g/dL (untransfused); lymphocyte count <5,000/µL; Bone marrow aspirate & biopsy normocellular for age with <30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia & bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets>100,000/µL or 50% improvement; Hemoglobin>11.0 g/dL (untransfused) or 50% improvement. (NCT00759603)
Timeframe: Responses assessed after 12 cycles, up to 48 weeks with interim assessments performed after 3, 6 and 12 cycles.

InterventionPercentage of Participants (Number)
Lenalidomide + Rituximab66

Reviews

3 reviews available for thalidomide and Fever

ArticleYear
Challenges in the diagnosis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome in developing countries-A decade of experience from North India.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Antipyretics; Antiviral Agents; Child; Colchicine; Developing Countries; Fever; Humans; Lymphadeniti

2022
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve

2020
Causes of birth defects: lessons from history.
    Congenital anomalies, 2011, Volume: 51, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Australia; Congenital Abnormalities; Female; Fever; History, 2

2011

Trials

4 trials available for thalidomide and Fever

ArticleYear
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H

2013
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
    American journal of hematology, 2014, Volume: 89, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr

2014
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-10, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem

2013
Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 298, Issue:3

    Topics: Acute-Phase Reaction; Adult; Cross-Over Studies; Cytokines; DNA Mutational Analysis; Double-Blind Me

2001

Other Studies

8 other studies available for thalidomide and Fever

ArticleYear
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).
    Journal of clinical immunology, 2023, Volume: 43, Issue:4

    Topics: Adalimumab; Anemia, Sideroblastic; Female; Fever; Humans; Immunoglobulins, Intravenous; Immunologic

2023
Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:4

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inh

2009
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
    International journal of hematology, 2011, Volume: 94, Issue:6

    Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Mult

2011
Thalidomide for treatment of PFAPA syndrome.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:3

    Topics: Adult; Fever; Humans; Immunosuppressive Agents; Lymphadenitis; Male; Periodicity; Pharyngitis; Recur

2007
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
    Chest, 2007, Volume: 131, Issue:5

    Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dys

2007
Adverse reactions to thalidomide in patients infected with human immunodeficiency virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:6

    Topics: Adult; CD4 Lymphocyte Count; Female; Fever; HIV Infections; Humans; Male; Prospective Studies; Skin;

1997
Thalidomide for distressing night sweats in advanced malignant disease.
    Palliative medicine, 1998, Volume: 12, Issue:3

    Topics: Fever; Humans; Hyperhidrosis; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Thalidomide

1998
Hansenosis of the neurotrophic type.
    Archives of dermatology, 1969, Volume: 99, Issue:5

    Topics: Adult; Fever; Humans; Leprosy; Male; Nervous System Diseases; Skin; Sulfones; Thalidomide

1969